Finnish
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

angiotensin/infarkti

Linkki tallennetaan leikepöydälle
Sivu 1 alkaen 40 tuloksia

Use of angiotensin I derivatives as an agent for the treatment and prevention of infarction-related cardiac injuries and disorders

Vain rekisteröityneet käyttäjät voivat kääntää artikkeleita
Kirjaudu sisään Rekisteröidy
FIELD OF THE INVENTION The present invention relates to the use of angiotensin I derivatives, including des-Aspartate angiotensin I in the treatment and/or prevention of infarction-related cardiac injuries and disorders. More particularly, the present invention contemplates a method for the

Use of angiotensin II receptor antagonists for treating acute myocardial infarction

Vain rekisteröityneet käyttäjät voivat kääntää artikkeleita
Kirjaudu sisään Rekisteröidy
The enzyme cascade of the renin-angiotensin system (RAS) comprises a series of biochemical events and, as is well known, there are a variety of approaches for using regulatory intervention to open up treatment possibilities, for example treatment of hypertension. Angiotensinogen, an

Use of angiotensin II receptor antagonists for treating acute myocardial infarction

Vain rekisteröityneet käyttäjät voivat kääntää artikkeleita
Kirjaudu sisään Rekisteröidy
The enzyme cascade of the renin-angiotensin system (RAS) comprises a series of biochemical events and, as is well known, there are a variety of approaches for using regulatory intervention to open up treatment possibilities, for example treatment of hypertension. Angiotensinogen, an
The invention relates to novel 1-(p-thienylbenzyl)imidazoles of formula (I), ##STR2## which are potent agonists of angiotensin (1-7) receptors and, because of the production land release of the vasorelaxant, antithrombotic, and cardio-protective messengers cyclic 3',5'-guanosine monophosphate (cGMP)
The invention relates to novel 1-(p-thienylbenzyl)imidazoles of formula (I), ##STR2## which are potent agonists of angiotensin (1-7) receptors and, because of the production hand release of the vasorelaxant, antithrombotic, and cardio-protective messengers cyclic 3',5'-guanosine monophosphate (cGMP)

Substituted triazoles as angiotensin II inhibitors

Vain rekisteröityneet käyttäjät voivat kääntää artikkeleita
Kirjaudu sisään Rekisteröidy
FIELD OF THE INVENTION This invention relates to novel compounds of the following formulae: ##STR1## The invention also relates to pharmaceutical compositions comprising a compound of the invention as the active ingredient, a method of treating a physiological condition in mammals that is mediated

Method for decreasing QT dispersion or inhibiting the progression of QT dispersion with an angiotensin II receptor antagonist

Vain rekisteröityneet käyttäjät voivat kääntää artikkeleita
Kirjaudu sisään Rekisteröidy
BACKGROUND OF THE INVENTION Angiotensin-converting-enzyme (ACE) inhibitors have been shown to reduce morbidity and mortality in patients with chronic heart failure and systolic left ventricular dysfunction as well as in patients post myocardial infarction. (See The CONSENSUS Trial Study Group.

Use of inhibitors of the renin-angiotensin system

Vain rekisteröityneet käyttäjät voivat kääntää artikkeleita
Kirjaudu sisään Rekisteröidy
FIELD OF THE INVENTION This invention relates to the use of inhibitors of the renin-angiotensin system. BACKGROUND OF THE INVENTION Wasting diseases may be categorised into generalised and localised wasting diseases. To deal first with generalised wasting, many disease processes can lead to

Use of inhibitors of the renin-angiotensin system

Vain rekisteröityneet käyttäjät voivat kääntää artikkeleita
Kirjaudu sisään Rekisteröidy
FIELD OF THE INVENTION This invention relates to the use of inhibitors of the renin-angiotensin system. BACKGROUND OF THE INVENTION Wasting diseases may be categorised into generalised and localised wasting diseases. To deal first with generalised wasting, many disease processes can lead to

Use of inhibitors of the renin-angiotensin system

Vain rekisteröityneet käyttäjät voivat kääntää artikkeleita
Kirjaudu sisään Rekisteröidy
FIELD OF THE INVENTION This invention relates to the use of inhibitors of the renin-angiotensin system. BACKGROUND OF THE INVENTION Wasting diseases may be categorised into generalised and localised wasting diseases. To deal first with generalised wasting, many disease processes can lead to

Combined use of angiotensin inhibitors and nitric oxide stimulators to treat fibrosis

Vain rekisteröityneet käyttäjät voivat kääntää artikkeleita
Kirjaudu sisään Rekisteröidy
BACKGROUND OF THE INVENTION 1. Field of the Invention This invention relates to methods and compositions for treating fibrosis. More particularly, the invention relates to the use of angiotensin inhibitors in combination with nitric oxide stimulators to inhibit the progression of fibrosis. 2.

Combined use of angiotensin inhibitors and nitric oxide stimulators to treat fibrosis

Vain rekisteröityneet käyttäjät voivat kääntää artikkeleita
Kirjaudu sisään Rekisteröidy
BACKGROUND OF THE INVENTION 1. Field of the Invention This invention relates to methods and compositions for treating fibrosis. More particularly, the invention relates to the use of angiotensin inhibitors in combination with nitric oxide stimulators to inhibit the progression of fibrosis. 2.

Fused heterocyclic compounds, having angiotensin II antagonistic activity

Vain rekisteröityneet käyttäjät voivat kääntää artikkeleita
Kirjaudu sisään Rekisteröidy
FIELD OF THE INVENTION The present invention relates to novel fused heterocyclic compounds having potent pharmacological actions and intermediates for the preparation thereof. More particularly, the present invention relates to fused heterocyclic compounds having potent anti-hypertensive activity

Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin

Vain rekisteröityneet käyttäjät voivat kääntää artikkeleita
Kirjaudu sisään Rekisteröidy
TECHNICAL FIELD This invention relates generally to pharmaceutical formulations for treating patients at elevated cardiovascular risk, and more particularly relates to dosage forms that combine a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin. BACKGROUND Many

Combination of an ADP-receptor blocking antiplatelet drug and antihypertensive drug and a method for preventing a cerebral infarction employing such combination

Vain rekisteröityneet käyttäjät voivat kääntää artikkeleita
Kirjaudu sisään Rekisteröidy
FIELD OF THE INVENTION The present invention relates to a novel combination of an ADP-receptor blocking antiplatelet drug, such as clopidogrel, and an antihypertensive drug, for example, an angiotensin II antagonist such as irbesartan, or an ACE inhibitor such as fosinopril, or a NEP/ACE inhibitor
Liity facebook-sivullemme

Täydellisin lääketieteellinen tietokanta tieteen tukemana

  • Toimii 55 kielellä
  • Yrttilääkkeet tieteen tukemana
  • Yrttien tunnistaminen kuvan perusteella
  • Interaktiivinen GPS-kartta - merkitse yrtit sijaintiin (tulossa pian)
  • Lue hakuusi liittyviä tieteellisiä julkaisuja
  • Hae lääkekasveja niiden vaikutusten perusteella
  • Järjestä kiinnostuksesi ja pysy ajan tasalla uutisista, kliinisistä tutkimuksista ja patenteista

Kirjoita oire tai sairaus ja lue yrtteistä, jotka saattavat auttaa, kirjoita yrtti ja näe taudit ja oireet, joita vastaan sitä käytetään.
* Kaikki tiedot perustuvat julkaistuun tieteelliseen tutkimukseen

Google Play badgeApp Store badge